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Rossella Libé*
Department of Endocrinology, French Network for Adrenal Cancer, Cochin Hospital, Paris, France
Adrenocortical carticnoma (ACC) is a rare malignancy with an incidence of 0.7–2.0
cases/million habitants/year. The diagnosis of malignancy relies on careful investigations
of clinical, biological, and imaging features before surgery and pathological examination
after tumor removal. Most patients present with steroid hormone excess or abdominal
mass effects, but 15% of patients with ACC is initially diagnosed incidentally. After the
diagnosis, in order to assess the ACC prognosis and establish an adequate basis for
treatment decisions different tools are proposed. The stage classification proposed by the
European Network for the Study of Adrenal Tumors (ENSAT) is recommended. Pathology
reports define the Weiss score, the resection status and the proliferative index, including
the mitotic count and the Ki67 index. As far as the treatment is concerned, in case of
tumor limited to the adrenal gland, the complete resection of the tumor is the first option.
Most patients benefit from adjuvant mitotane treatment. In metastatic disease, mitotane
is the cornerstone of initial treatment, and cytotoxic drugs should be added in case of
progression. Recently, the First International Randomized (FIRM-ACT) Trial in metastatic
ACC reported the association between mitotane and etoposide/doxorubicin/cisplatin
(EDP) as the new standard in first line treatment of ACC. In last years, new targeted
therapies, including the IGF-1 receptor inhibitors, have been investigated, but their
efficacy remains limited. Thus, new treatment concepts are urgently needed. The ongoing
“omic approaches” and next-generation sequencing will improve our understanding of
the pathogenesis and hopefully will lead to better therapies.
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Introduction
Adrenocortical carticnoma (ACC) is a rare malignancy with an incidence of 0.7–2.0 cases/million
habitants/year. It occurs at any age, with two peak incidence: the first one in the first decade and
the second one between 40 and 50 years. Women are most frequently affected (55–60%) (Kebebew
et al., 2006).
Molecular Oncogenesis and the Epigenetic Aspects
In the past, progress in identifying genes involved in ACC came mainly from the study
of familial diseases (Else et al., 2014). ACC were frequently associated to the Li–Fraumeni
syndrome, due to germline TP53 mutations and the Beckwith–Wiedemann syndrome, due to
alterations of the insulin-like growth factor IGF2. At somatic level, inactivating mutations of TP53
and activating mutations of the proto-oncogene β-catenin (CTNNB1) were the most frequent
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mutations identified in ACC. Recently, thanks to genomic
approaches, including exome sequencing, not only TP53 and
CTNNB1 were confirmed as implicated in ACC tumorigenesis,
but also ZNRF3 (Zinc and ring finger protein 3) was the most
frequently altered gene (21%) (Assié et al., 2014a). Interestingly,
ZNRF, as CTNNBI, belong to theWNT pathway and it seems that
the mutations in the two genes are mutually exclusive.
Moreover, by comparative genomic hybridization (CGH),
chromosomal gains at 5, 7, 12, 16, 19, and 20 and losses at 13 and
22 were observed in ACC. Concerning the epigenetic changes,
a specific CpG island methylator phenotype was identified in
ACC associated to the hypermethylation of the promoters of
specific genes as H19, PLAGL1, G0S2, and NDRG2. In addition,
some studies identified a significant up-regulation of miR-483
associated to a downrefulation of miR-195 and miR-335 in ACC
(Assié et al., 2014b).
Diagnosis
Endocrine Work-up
The diagnosis of malignancy relies on careful investigations
of clinical, biological, and imaging features before surgery and
pathological examination after tumor removal. Most patients
(40–60%) present steroid hormone excess (glucocorticoids,
mineralocorticoids, androgens) or abdominal mass effects (30%),
but 15–20% of patients with ACC are initially diagnosed
incidentally (Else et al., 2014).
The European Network for the Study of Adrenal Tumors
(ENS@T) suggests a pre-operative hormonal workup for
suspected ACC (www.ensat.org). In particular, the assessment
of basal cortisol, ACTH, dehydroepiandrostenedione sulfate,
17-hydroxyprogesterone, testosterone, androstenedione, and
estradiol as well as a dexamethasone suppression test and urinary
free cortisol are recommended. In the last years, it seems more
evident that some ACC, previously considered as non-secreting,
in fact can secrete some urine steroid metabolites and recently
urine steroid metobolomic analysis have been introduced in
routine use (Arlt et al., 2012).
Imaging
Traditional and functional imagings are able to diagnose
correctly an adrenal mass as ACC in most of the cases. The risk
for ACC increases with tumor size, with the index of suspicion
increasing for tumors >4 cm (sensitivity, 97%; specificity, 52%)
and >6 cm (sensitivity, 91%; specificity, 80%) (Sturgeon et al.,
2006). Unfortunately, masses from 1 to 4 cm in diameter are
diagnostically challenging. Generally, most of the ACC are large,
heterogeneous with irregular margins. Necrosis, hemorrhage or
calcification can be associated.
Currently, no single imaging method can characterize a
localized adrenal mass as ACC. Regarding traditional imaging,
abdominal computed tomography (CT) scan is mandatory in
suspicion of ACC: many studies have established a threshold
of ≤10 Hounsfield Unit (HU) in unenhanced CT for the
diagnosis of benign lesion. When the basal density is >10 UH,
the contrast media washout is helpful to discriminate the benign
adrenal lesions from the ACC. An absolute washout >50%
suggests a benign adrenal lesion. As well as CT scan is
fundamental to define the disease staging (Ilias et al., 2007; Zhang
et al., 2010; Young, 2011), all patients with ACC must perform a
chest CT scan in order to detect pulmonary metastases before
surgery.
The state of art of the Magnetic Resonance Imaging (MRI)
is less known. In case of suspicion of ACC, when the CT scan
cannot perfectly characterize the adrenal lesion, three major
characteristics of MRI are helpful in the ACC diagnosis: the
presence of isointense to hypointense signal on T1-weighted
images, a hyperintense signal on T2-weighted images and an
heterogeneous signal drop on chemical shift (Elsayes et al., 2004;
Bharwani et al., 2011).
Regarding functional imaging, ACC showed high 18F-
fluorodeoxyglucose (FDG) uptake (Boland et al., 2011; Deandreis
et al., 2014) with a cut-off value > 1.45 for adrenal to liver
maximum standardized uptake value (SUV), as reported in a
series of 77 patients with surgical proven diagnosis of adrenal
adenoma or ACC (Groussin et al., 2009). As the chest and
abdominal CT scan, FDG-PET is important for disease staging
and prognosis (Leboulleux et al., 2006), but its routine use still
needs validation.
In recent years, a new tracer, the metomidate ([11C]MTO)
can be useful to prove the adrenocortical origin because it
specifically binds to adrenocortical CYP11B enzymes, which
catalyze the final steps of steroid synthesis. In a study
of 11 patients, ACC showed a higher tracer uptake at
[11C]MTO-PET compared to normal adrenal gland and liver
(Hahner et al., 2008).
Pathology
The pathological assessment is the key to the final diagnosis
of ACC, but it remains challenging. First, as the ACC can
be non-secreting tumor, the adrenocortical origin of the mass
must be established. The determination of steroidogenic factor 1
(SF-1) expression has proved as the most valid marker (Duregon
et al., 2009; Sbiera et al., 2009). Second, multiple parameters
(macroscopic and microscopic) have to be evaluated in order to
discriminate benign from malignant tumor.
Macroscopy revelead that ACC are usually large,
heterogeneous, with a surface ranges from brown to orange
to yellow depending on the lipid content of their cells. Necrosis
is almost always present. Importantly, the presence of a tumoral
invasion at different levels, as the tumor capsule, the extra-
adrenal soft tissue or direct invasion of lymphatic channels,
blood vessels are the key features of ACC.
Microscopically, the Weiss score is still the best validated
score. It is composed of nine items (three concerning the
architecture, three the nucleus, and three the presence of any type
of invasion) and the presence of one item scores 1. The sum of the
positive items defines the final score. It is established that a Weiss
score≥ 3 define an ACC, whereas scores between 0 and 2 defines
the adrenal adenoma, even if sometimes aWeiss score of 2 can be
suspicious (Weiss, 1984).
The major problem is the reproducibility of this score and
in particular the inter-individual reproducibility. Recently, the
practice of the Weiss score through virtual microscopy has been
improved by the 12 pathologists of the French network for
Adrenal Cancer COMETE (Tissier et al., 2012).
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Proliferation index, as Ki67 immunomarker or mitotic count,
can help to define the diagnosis and prognosis of ACC. It
is well-established that ACC generally showed a Ki67 ≥ 5%.
Recent studies have been demonstrated that Ki67 is a powerful
prognostic marker in both localized and metastatic ACC to
guide treatment decision (Berruti et al., 2010; Libé et al.,
2014; Beuschlein et al., 2015). Moreover, a mitotic count >20
mitoses/50 HPF defines a “high grade ACC” with a worst
prognosis compared to “low grade ACC” with ≤ 20 mitoses/50
HPF (Miller et al., 2010).
Staging
Tumor staging is a widely used tool to assess prognosis in patients
with cancer. For ACC, the tumor–node–metastasis (TNM)
classification proposed by ENS@T (Table 1) is recommended
(Fassnacht et al., 2009). This staging system, defines stage I and
stage II as strictly localized tumors with a size of ≤5 or >5 cm,
respectively. Stage III ACC are characterized by infiltration in
surrounding tissue, positive regional lymph nodes or a tumor
thrombus in the vena cava and/or renal vein, whereas stage IV is
defined by the presence of distantmetastasis. The high prognostic
potential of the ENS@T staging system has been established in
the large cohort of the German ACC registry (Beuschlein et al.,
2015) and has been confirmed in the independent SEER cohort
(Lughezzani et al., 2010) which demonstrates its superiority to
the staging system published by the Union Internationale Contre
Le Cancer (UICC).
Prognosis
Three major criteria are mandatory in order to define the disease
free survival for the localized ACC (stage I, II, and some III) and
the overall survival for stage IV ACC: (1) staging; (2) resection
status “R”; (3) Grading (proliferation index, as Ki67% andmitotic
count).
Staging
As mentioned above, staging is mandatory to assess prognosis.
Five-year stage-dependent survival is 66–82% for stage I, 58–
64% for stage II, 24–50% for stage III, and 0–17% for stage IV,
according to different series (Icard et al., 2001; Fassnacht et al.,
2009; Lughezzani et al., 2010; Kerkhofs et al., 2013).
TABLE 1 | ENS@T classification.
ENS@T stage
I T1, N0, M0
II T2, N0, M0
III T3–T4, N1
IV T1–T4, N0–N1, M1
T1, tumor ≤ 5 cm; T2, tumor > 5 cm; T3, histologically proven tumor invasion of
surrounding tissue; T4, tumor invasion of adjacent organs or venous tumor thrombus
in vena cava or renal vein. Venous tumor thrombus is only a criterion in the ENSAT
classification.
N0, negative lymph nodes; N1, positive lymph nodes.
M0, absence of distant metastases; M1, presence of distant metastases.
Resection Status “R”
In localized ACC, surgery is the single most important
intervention and the complete resection (R0) correlates with a
better prognosis (Bilimoria et al., 2008). In fact, an incomplete
microscopic resection (R1), an incomplete macroscopic resection
(R2) or unknown resection (Rx) are associated with the worst
overall survival of 20 and 15%, respectively (Bilimoria et al.,
2008).
Grading
Proliferation index, as Ki67 and mitotic count help to assess
the ACC prognosis. Very recently, a large European study in
localized ACC identified Ki67 as the single most important
factor predicting recurrence in patients following R0 resection
(Beuschlein et al., 2015). Thus, evaluation of Ki67 indices should
be introduced as standard grading in all pathology reports of
ACC patients (Beuschlein et al., 2015). More recently, in a large
European study on stage IV ACC, the tumor grading, as the
association of the Ki67 and the Weiss score, has been considered
as an important prognostic parameter of overall survival (Libé
et al., 2014), confirming the data on the mitotic count showed in
a previous French series (Assie et al., 2007).
Molecular Markers
Molecular markers issued form genomic and epigenomic
analyses are emerging and need to be confronted to the previous
mentioned criteria. Hypermethylation status, miRNA profile or
driver genes mutations, as TP53, ZNRF3, β-catenin constitute
valuable candidates that could integrate a future clinico-
molecular prognostic classification of ACC patients (Assié et al.,
2014a).
Treatment
Currently, the only curative approach to ACCs is complete
tumor resection. Adjuvant therapies aim to decrease the risk of
recurrence. These two approaches address mainly to localized
ACCs (stages I, II, some III), also called “ACC amenable to radical
resection.” For “unresectable or metastatic ACC” all therapy
must be considered palliative, even in some cases (only two
tumoral organs, included adrenal), surgery can be considered as
an option.
The Figure 1 showed the current treatment flow-chart for
patients with “Localized ACC” and for those with “Metastatic
ACC.”
Localized ACC
Surgical Treatment
For “localized ACC” (“ACC amenable to radical resection”),
complete surgical resection (R0) is the treatment of choice.
Appropriate preoperative evaluation and operative planning
by a surgeon experienced in the resection of ACC (>10
adrenalectomy/year/surgeon) is of the most importance to assure
optimal outcome. Different key questions concern the optimal
surgical approach: (1) open adrenalectomy (OA) vs. laparoscopic
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FIGURE 1 | Flow chart for ACC management. Abbreviation: R0, complete resection; R1, microscopic incomplete resection; R2, macroscopic incomplete
resection; Rx, unknown; EDP, etoposide, doxorubicine, cisplatin.
adrenalectomy (LA) (2) lymph nodes dissection (LND) (3) large
surgery to the adjacent organs (in bloc surgery).
The choice of the best surgical approach (OA vs. LA) remains
controversial. OA should still be regarded as standard treatment
for ACC, mainly in the case of an infiltrating tumor or suspected
lymph nodes (presumable stage III), and LA should be performed
only in selected cases (tumor< 5 cm, absence of higher FDG PET
uptake, experimented surgeon).
Up to now, published data comparing the efficacy (and safety)
of LA vs. OA for ACC are not definitive, as all the series
are retrospectives, with limited number of patients, no follow-
up and many biais. Indeed, in two studies has been reported
a recurrence rate of 86% in the OA group and 100% in the
LA group (with local recurrence and peritoneal carcinomatosis)
(Gonzalez et al., 2005; Grubbs et al., 2010). These data has
been confirmed by Leboulleux et al. (2010), which showed
that peritoneal carcinomatosis occurred in only 25% of patients
treated by OA, compared to 60% in LA group. In contrast, other
studies reported evidence that LA may be comparable to OA in
patients with stage 1 and 2 ACC, in terms of recurrence-free
survival. A case-control study from the German ACC Registry
Group reported no difference in overall or disease-free survival,
tumor capsule violation, or peritoneal carcinomatosis among
117 patients undergoing OA and 35 patients undergoing LA
for stage 1–3 ACCs less than 10 cm. However, many patients in
the OA group had stage 3 disease and only four patients (11%)
undergoing LA were found to have stage 3 disease, potentially
introducing a bias toward more advanced disease in the OA
group, and 37% of all patients had no data regarding margin
status (Brix et al., 2010).
Although no standard management has been established
concerning the extent of the first surgery, and in particular
the LND, a recent retrospective study, suggests that it might
improve both diagnostic accuracy and therapeutic outcome, with
a significant reduced risk of tumor recurrence for LND patients
(Reibetanz et al., 2011).
As far as, the extension of surgery is concerned, it seems to
be little benefit of systematically ipsilateral nephrectomy in the
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absence of gross local invasion (Gaujoux et al., 2011). However,
in order to achieve the complete resection R0, it is mandatory,
in case of large tumor and suspicious of organ adjacent invasion
or infiltration, to perform a “in bloc” resection, including tumor
thrombus embolectomy (Gaujoux and Brennan, 2012).
Adjuvant Therapy
The natural history of recurrence after surgery remains uncertain,
but even in case of complete resection, the rate of local recurrence
remains important and ranges between 19 and 34%, on the
basis of tumor stage. For this reason, adjuvant therapy can be
associated after surgery and include mitotane and tumoral bed
irradiation.
Mitotane
Mitotane is a derivate of the insecticide
dichlorodiphenyltrichloroethane (DDD), with adrenolytic
and citotoxic activity: in particular, mitotane metabolites inhibit
several enzymes in the adrenocortical steroidogenensis pathway,
mainly at the level of the cholesterol side-chain cleavage enzymes
CYP11A1 and CYP11B1.
In terms of adjuvant therapy in “localized ACC” after surgery,
a large retrospective analysis comparing two independent cohorts
(Terzolo et al., 2007) demonstrated that patients with adjuvant
mitotane had a significantly improved recurrence-free survival.
As this is a retrospective study, it remains a matter to discussion.
This is particularly true for patients with presumably low
or intermediate risk of recurrence (defined by R0 resection,
absence of metastases and Ki67 < 10%) (Berruti et al., 2010).
For these patients, a prospective international randomized trial
(ADIUVO: https://www.epiclin.it/adiuvo) comparing treatment
with mitotane vs. a “watch and see” strategy, can be proposed.
Mitotane Therapy Management
The mechanism of mitotane action and pharmacokinetics data
are poorly understood. In fact, the variability of individual plasma
levels reached by a given dosage is high and it remains unclear
which enzyme metabolize mitotane in human, although there
is the first evidence that CYP2B6 might be involved. The dose
is initiated at 1 g twice daily and increases every 4–7 days by
0.5–1 g/day until a daily dose of 6.0 g/day is reached. Moreover,
two different regimens (“high dose” and “low dose”) have been
proposed, but no significant difference in mitotane levels and
adverse events has been described (Kerkhofs et al., 2010). Several
studies demonstrated that a mitotane plasma level ≥14mg/l
is required for clinical efficacy and is associated to a better
overall survival (Hermsen et al., 2011). Moreover, the same study
demonstrated that even mitotane level > 8mg/l seems to be
associated to a better outcome (Hermsen et al., 2011). Mitotane
comes with significant toxicity, like dizziness, vertigo, central
nervous system disturbances and gastro-intestinal symptoms.
Moreover, as the adrenolytic action of mitotane, all patients
develop an adrenal insufficiency, which has to be replaced with
a high dosage of hydrocortisone. In fact mitotane induces the
cytochrome P450 3A4 (CYP3A4) leading to lower the blood
levels of many drugs (including the steroids, anti-hypertensives,
antibiotics) (Kroiss et al., 2011a).
Radiotherapy
In order to reduce the risk of local recurrence, external radiation
therapy of the tumor bed can be an option. In the literature, three
retrospective studies with a little number of patients tempt to
solve the questions: two of them showed a benefit in preventing
local recurrence, but none of them demonstrates an advantage
in term of overall survival (Fassnacht et al., 2006; Sabolch et al.,
2011; Habra et al., 2013). Currently, an adjuvant therapy is
recommended only in case of a particularly high risk for local
recurrence (R1 resection) (Berruti et al., 2010).
Metastatic ACC
In metastatic disease, different parameters had to be considered:
the tumoral volume, the number of metastatic organs, the
progression slopes. Debulking surgery is only of benefit in
patients with a tumoral mass respectable, a limited number
of tumoral organs (≤2), with a slight progression and in case
of severe hormone excess that cannot be controlled otherwise.
Instead, medical therapy should be initiated as soon as the
diagnosis is established.
Mitotane remains the only drug approved by the U.S food and
drug Administration (FDA) and European Medicine Executive
Agency (EMEA) for treatment of “metastatic ACC.” An overview
collecting different studies showed that the objective response
rate is at best 24% (De Francia et al., 2012).
Recently, the First International Randomized trial in Locally
Advanced and metastatic Adrenocortical Carcinoma treatment
(FIRM-ACT) trial included 304 patients with metastatic ACC
and compared the association of mitotane with etoposide-
cisplatin-doxorubicine (M-EDP) with mitotane-streptozotocin
(M-Sz) as a first-line or second-line treatment. It was shown
that the M-EDP was associated with a better progression-free
survival and objective response rate compared to M-Sz (5.0 vs.
2.1 months, 23.2 vs. 9.2%, respectively), although no significant
difference was demonstrated on overall survival (Fassnacht et al.,
2012). Based on these data, M-EDP is considered as first-line
therapy for patients requiring cytotoxic treatment.
For patients failing M-EDP, it has been proposed, as
second line chemotherapy, the combination of gemcitabine and
capecitabine, leading a disease stabilization for at least 6 months
in 29% of patients (Sperone et al., 2009).
Other Treatments
Loco-regional Approaches
In case of metastatic ACC or ACC recurrence local treatment
modalities, such as radiofrequency ablation (RFA) or transarterial
chemoembolization (TACE) are recommended.
None of these methods has been explored in clinical trials.
However, both methods are an alternative to surgery, when
surgery is not desired or contro-indicated, or in order to control
the disease locally. RFA has been successfully employed in
the palliative setting, rendering patients free of liver metastasis
(Ripley et al., 2011). TACE, localized chemoembolization, is
based on a selective embolization with injection of a high
intratumor levels of cytotoxic substances with a minimum of
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systemic effects. Predictors of response were a size of <3 cm and
high lipidol uptake (Soga et al., 2009).
Targeted Therapy
Up to now, current treatments fail in many patients with
metastatic ACC and different molecular target therapies have
been tested. The first trial targeted the epidermal growth
factor receptor (EGFR) but the combination of erlotinib and
gemcitabine failed to give an objective response (Quinkler et al.,
2008). The vascular endothelial growth factor (VEGF) is another
potential target, as highly expressed in ACC. In a trial with
bevacizumab, a humanized anti-VEGF monoclonal antibody, a
progression disease was demonstrated in all of the 10 patients
enrolled (Wortmann et al., 2010). Similarly, a multitirosine –
kinase inhibitor, sorafenib in combination with paclitaxel did not
demonstrate any efficacy in a cohort of 25 patients (Berruti et al.,
2012). Only the sunitinib, a multi-TKI, demonstrated in a cohort
of 35 patients 14% of stable disease. In this trial concomitant
administration of mitotane diminished plasma levels of sunitinib
and its active metabolite (Kroiss et al., 2011b).
Recently, drugs targeting IGF-2 seemed to be very promising.,
as IGF-2 is the most-up regulated gene in ACC. Recently, a
phase 2 study used a IMCA12 (cixutumab), a fully humanized
IGF-1R antibody showed a lack of efficacy in a cohort of 19
patients (Lerario et al., 2014). In another study, the association of
cituximab with temsirolomus, an inhibitor of mammalian targets
of IGF-1R signaling, led to a stable disease in 42% of the patients
(Naing et al., 2013).
The disappointing results of a huge phase 3 trial
“GALACCTIC” with a highly specific IGF-1R inhibitor
linstinib (OSI-906) in a cohort of 138 metastatic ACC have been
recently published: the progression-free and overall survival did
not differ between the “OSI-906” and placebo groups (Fassnacht
et al., 2015).
Finally, like in the disease heterogeneity, it appears that
using one single agent is not sufficient to induce an objective
response. Trials with new targeted substances are under study
and alternative combination therapy may be promising.
Recently, as [123I]IMTO single-photon emission CT imaging
showed high tracer uptake in issue of adrenocortical origin,
[131I]IMTO might represent a suitable compound for targeted
radionuclide therapy. [131I]IMTO treatment in 11 patients with
advanced ACC resulted in median progression-free survival for
1 month in 6 patients who responded to therapy (Hahner et al.,
2012).
Follow-up
The follow-up management is not well-standardized yet, but,
as ACC is an aggressive malignant tumor, patients should be
followed every 3 months during and after initial treatment. Only
after a recurrence free-time of 2–3 years the surveillance intervals
may be increased to 6 months until a completion of follow-up for
a total of 5 years. After 5 years of disease-free, the surveillance
can be proposed every 1–2 years, because, although rare, some
patients can relapse tardily.
Patients should undergo a complete physical examination,
hormonal investigations and a complete imaging work-up,
including chest and abdominal CT scan. A [18F] FDG-PET may
also be considered, even if it’s not considered mandatory in the
follow-up of ACC patients.
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